Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
blinatumomab (Amgen)
- Development stage
- Approved
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Blinatumomab SC1 refers to a specific subcutaneous formulation of blinatumomab, a first-in-class bispecific T-cell engager (BiTE) developed by Amgen. Blinatumomab is designed to treat B-cell precursor acute lymphoblastic leukemia (B-ALL) by simultaneously binding to CD19 on B-lineage cells and CD3 on T cells. This dual binding facilitates the formation of a cytolytic synapse, leading to the redirected lysis of malignant B cells by the patient's own T cells. While the standard intravenous formulation (Blincyto) requires a continuous 28-day infusion via a portable pump, the SC1 formulation is being developed to provide a more convenient subcutaneous administration route, potentially reducing the treatment burden and improving patient quality of life. It is currently being evaluated in clinical trials for both relapsed/refractory and minimal residual disease (MRD) positive B-ALL.
- Brand names
- Blincyto
- Other names
- blinatumomab SC1subcutaneous blinatumomabblinatumomab SC
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on blinatumomab (Amgen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on blinatumomab (Amgen).